Literature DB >> 34354370

An Immune-Related Gene-Based Signature as Prognostic Tool in Ovarian Serous Cystadenocarcinoma.

Fengjuan Shi1, Tongning Deng2, Jian Mo1, Huiru Wang1, Jianxun Lu3,4.   

Abstract

BACKGROUND: Ovarian serous cystadenocarcinoma (OSCC) is a life-threatening malignancy with poor prognosis. Therefore, the identification of immune-related genes associated with OSCC prognosis may reveal new targets of immunotherapy for OSCC. PATIENTS AND METHODS: The gene expression profiles of overlapped genes were extracted by weighted gene co-expression network analysis (WGCNA) to identify immune-related modules. Significant genes were identified by univariate Cox regression analysis of model genes. Model characteristic genes were obtained by least absolute shrinkage and selection operator (LASSO) analysis and used to calculate a "signature index". The model's ability to predict prognosis in OSCC patients was assessed using time-dependent receiver operator characteristic curves. Differences in the biological processes and Kyoto Encyclopedia of Genes and Genomes pathways between groups with high or low signature index were assessed using gene set enrichment analysis (GSEA). The types of immune cells and their abundance in the two index groups were explored by single-sample GSEA.
RESULTS: The expression profiles of 3517 overlapped genes were extracted by WGCNA, and nine modules related to the immune system of OSCC were obtained. The expression profiles of 114 hub genes were then subjected to LASSO analysis. Among them, 10 immune-related genes were significant, of which six were identified as model characteristic genes and were used to calculate the signature index. Moreover, 24 types of immune cells were identified in the tumor microenvironment, and their abundance was explored in high- and low-signature index groups of two datasets.
CONCLUSION: ARHGEF18, PLEKHA7, MTOR, VPS45, BRCA1, and HINT2 were identified as characteristic genes and used to develop a new immune-related gene-based signature as a promising prognostic biomarker for OSCC.
© 2021 Shi et al.

Entities:  

Keywords:  immune-related genes; ovarian serous cystadenocarcinoma; prognostic biomarker; signature index

Year:  2021        PMID: 34354370      PMCID: PMC8331220          DOI: 10.2147/IJGM.S313791

Source DB:  PubMed          Journal:  Int J Gen Med        ISSN: 1178-7074


  32 in total

Review 1.  Tumor microenvironment: Sanctuary of the devil.

Authors:  Lanlan Hui; Ye Chen
Journal:  Cancer Lett       Date:  2015-08-11       Impact factor: 8.679

2.  Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer.

Authors:  Mingzhu Yin; Xia Li; Shu Tan; Huanjiao Jenny Zhou; Weidong Ji; Stefania Bellone; Xiaocao Xu; Haifeng Zhang; Alessandro D Santin; Ge Lou; Wang Min
Journal:  J Clin Invest       Date:  2016-10-10       Impact factor: 14.808

3.  limma powers differential expression analyses for RNA-sequencing and microarray studies.

Authors:  Matthew E Ritchie; Belinda Phipson; Di Wu; Yifang Hu; Charity W Law; Wei Shi; Gordon K Smyth
Journal:  Nucleic Acids Res       Date:  2015-01-20       Impact factor: 16.971

4.  The Molecular Signatures Database (MSigDB) hallmark gene set collection.

Authors:  Arthur Liberzon; Chet Birger; Helga Thorvaldsdóttir; Mahmoud Ghandi; Jill P Mesirov; Pablo Tamayo
Journal:  Cell Syst       Date:  2015-12-23       Impact factor: 10.304

Review 5.  Personalising Treatment for High-Grade Serous Ovarian Carcinoma.

Authors:  E Cojocaru; C A Parkinson; J D Brenton
Journal:  Clin Oncol (R Coll Radiol)       Date:  2018-06-19       Impact factor: 4.126

Review 6.  Immune Therapy Opportunities in Ovarian Cancer.

Authors:  Lana E Kandalaft; Kunle Odunsi; George Coukos
Journal:  Am Soc Clin Oncol Educ Book       Date:  2020-05

7.  NCBI GEO: archive for functional genomics data sets--update.

Authors:  Tanya Barrett; Stephen E Wilhite; Pierre Ledoux; Carlos Evangelista; Irene F Kim; Maxim Tomashevsky; Kimberly A Marshall; Katherine H Phillippy; Patti M Sherman; Michelle Holko; Andrey Yefanov; Hyeseung Lee; Naigong Zhang; Cynthia L Robertson; Nadezhda Serova; Sean Davis; Alexandra Soboleva
Journal:  Nucleic Acids Res       Date:  2012-11-27       Impact factor: 16.971

Review 8.  Profiling Prostate Cancer Therapeutic Resistance.

Authors:  Cameron A Wade; Natasha Kyprianou
Journal:  Int J Mol Sci       Date:  2018-03-19       Impact factor: 5.923

9.  Acquisition of a side population fraction augments malignant phenotype in ovarian cancer.

Authors:  Koji Yamanoi; Tsukasa Baba; Kaoru Abiko; Junzo Hamanishi; Ken Yamaguchi; Ryusuke Murakami; Mana Taki; Yuko Hosoe; Susan K Murphy; Ikuo Konishi; Masaki Mandai; Noriomi Matsumura
Journal:  Sci Rep       Date:  2019-10-02       Impact factor: 4.379

10.  Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.

Authors:  Nicholas McGranahan; Rachel Rosenthal; Crispin T Hiley; Andrew J Rowan; Thomas B K Watkins; Gareth A Wilson; Nicolai J Birkbak; Selvaraju Veeriah; Peter Van Loo; Javier Herrero; Charles Swanton
Journal:  Cell       Date:  2017-10-26       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.